This module captures the shared downstream cAMP/PKA segment for somatotroph pituitary adenoma mechanisms. Disorder entries should keep the gene-specific upstream lesion explicit, then declare conformance on the convergent cAMP/PKA nodes. AIP reaches the module through reduced inhibitory/catabolic restraint; GPR101 reaches it primarily through GPCR dosage gain; GNAS reaches it through constitutive Gs-alpha activity. Reported GPR101 point variants should conform to this module only when their causal status is supported in the disorder entry.
Increased somatotroph cAMP availability
convergence point
Somatotroph-lineage cells have increased intracellular cAMP availability because cAMP synthesis is increased, inhibitory restraint is reduced, cAMP degradation is reduced, or a combination of these mechanisms applies.
Downstream
-
Increased cAMP/PKA signaling in somatotrophs
Increased cAMP availability activates the cAMP/PKA signaling cassette in somatotroph-lineage cells.
Show evidence (2 references)
"A subset of human growth hormone (GH)-secreting pituitary tumours, characterized by elevated GH secretion, cyclic AMP levels, and adenylyl cyclase activity, carries mutations in the gene that encodes the alpha-chain of Gs."
This establishes elevated cAMP and adenylyl cyclase activity as a recurrent biochemical state in GH-secreting pituitary tumors with GNAS activation.
"Moreover, we showed that GPR101 can strongly activate the cAMP pathway, for which the mitogenic effects in pituitary somatotropes are well established."
This supports cAMP activation as the shared downstream state for GPR101-driven somatotroph disease, especially when GPR101 dosage is increased in X-linked acrogigantism.
Increased cAMP/PKA signaling in somatotrophs
central effector
Elevated cAMP activates protein kinase A and downstream transcriptional effectors in somatotroph-lineage cells, creating a shared proliferative and secretory signaling state across multiple genetic etiologies.
Downstream
-
Increased growth hormone secretion
cAMP/PKA signaling increases the secretory drive of somatotroph-lineage pituitary tumor cells.
-
Somatotroph proliferation and adenoma growth
cAMP/PKA signaling contributes to proliferation of somatotroph-lineage cells and growth of GH-secreting pituitary adenomas.
Show evidence (2 references)
"As in the construct containing the nonmutant receptor, the two mutant constructs resulted in increased cAMP signaling in GH3 cells in an in vitro reporter assay, both at baseline and in the presence of 10 μM forskolin, a direct stimulator of adenylyl cyclase (Fig. 4F)."
This experimentally connects GPR101 activation to increased cAMP signaling in pituitary GH3 cells.
"By substitution of a single amino acid (Arg-201 or Gln-227), these mutations inhibit the intrinsic GTPase activity of alpha s, thus stabilizing the protein in its active conformation."
This supports constitutive Gs-alpha activation as a route into sustained cAMP/PKA signaling in GH-secreting pituitary tumors.
Increased growth hormone secretion
consequence
Somatotroph-lineage cells release excess growth hormone downstream of cAMP/PKA overactivation, producing biochemical growth hormone excess and the clinical gigantism/acromegaly spectrum.
Show evidence (2 references)
"When the mutation was transfected into rat GH3 cells, it led to increased release of growth hormone and proliferation of growth hormone-producing cells."
This directly supports increased GH secretion as a downstream effect of GPR101 activation in a pituitary cell model.
"A subset of human growth hormone (GH)-secreting pituitary tumours, characterized by elevated GH secretion, cyclic AMP levels, and adenylyl cyclase activity, carries mutations in the gene that encodes the alpha-chain of Gs."
This links elevated GH secretion with cAMP pathway activation in human pituitary tumors.
Somatotroph proliferation and adenoma growth
consequence
cAMP-responsive somatotroph-lineage cells expand, producing pituitary hyperplasia or GH-secreting adenoma growth depending on the initiating genetic context and timing.
Show evidence (2 references)
"When the mutation was transfected into rat GH3 cells, it led to increased release of growth hormone and proliferation of growth hormone-producing cells."
This directly supports somatotroph-lineage proliferation downstream of GPR101 activation.
"The discovery of mutant alpha s proteins in human tumours suggests that the alpha s gene can be converted into an oncogene, called gsp, in cells that proliferate in response to cyclic AMP."
This supports cAMP-responsive proliferation as the tumorigenic context for activating GNAS mutations in pituitary tumors.